The combination is commonly used in situations involving certain distressing symptoms across relevant therapeutic domains.

The combination is applied in addressing integrated symptomatic relief for acute, mild-to-moderate discomfort. It is relevant in conditions presenting with systemic or localized discomfort such as muscle aches, backache, dental pain (toothache), period pain (dysmenorrhea), and headache syndromes including episodic tension headaches and migraine attacks. It is also applied in addressing acute symptomatic episodes, particularly those associated with colds and influenza, by helping with reducing elevated body temperature (fever) and alleviating associated body aches.

The combination contributes to improved day-to-day comfort during periods of heightened symptoms. It is used when groups of symptoms appear suddenly or interfere with daily functioning, providing support that helps ease the overall symptom burden.

Quick Fact: Relief for Episodic Discomfort The combination is frequently used during phases of increased distress or discomfort associated with recurrent or episodic manifestations (like headaches or menstrual pain), where short-term symptomatic assistance is needed.

Eligibility Scope

The eligibility profile for Finimal (Acetaminophen, Caffeine) is strictly defined by official regulatory labeling, setting clear rules on which populations may use the medicine and which are restricted or prohibited.

Populations for whom use is allowed (as stated in label): Adults and adolescents, typically those 12 years of age and older, are the approved age groups for most formulations.

Populations for whom use is contraindicated:

• Patients with a known hypersensitivity to Acetaminophen (Paracetamol), Caffeine, or any other excipients in the product.
• Patients with severe hepatic impairment (severe liver disease).
• Children under the minimum age threshold (e.g., under 12 years of age).

Condition-specific eligibility rules:

• Use requires caution in patients with renal impairment, mild to moderate hepatic insufficiency, and in patients with chronic alcoholism.
• The presence of certain pre-existing conditions, such as cardiovascular disease, may require caution due to the stimulant effects of the caffeine component.

Pregnancy and lactation eligibility status (if explicitly documented):

• The product is generally not recommended for use during pregnancy.
• The product is generally not recommended for use while breastfeeding.

---

Eligibility Classifications (High-Level)

Eligibility severity classification	Regulatory basis (Example)
Contraindicated (Absolute prohibition)	Severe hepatic impairment
Not Recommended (Specific restriction)	Pregnancy and lactation
Use with Caution (Conditional restriction)	Renal or mild hepatic impairment

Connection to the overall eligibility profile: The regulatory documents establish eligibility through absolute contraindications related to allergy status and severe organ dysfunction, and through conditional restrictions related to age, organ function, and specific physiological states, which together define the official population for whom the medicine is intended.

Interactions with other medicines and products

The official regulatory profile for this combination product is defined by documented interactions involving both Acetaminophen and Caffeine, categorized by their effect on exposure or regulatory restriction.

Co-Administration Restrictions and Hepatotoxicity Risk

Co-administration with other paracetamol-containing products is formally advised against or contraindicated due to the severe, documented risk of exceeding the safe dose, which can lead to liver toxicity. The regulatory profile notes that the hazard of overdose is greater for individuals with non-cirrhotic alcoholic liver disease or underlying hepatic impairment. Furthermore, the official documents state that chronic or excessive alcohol consumption increases the risk of acetaminophen-induced liver damage.

Pharmacokinetic and Exposure-Altering Interactions

Hepatic enzyme inducers, such as certain anticonvulsants (phenytoin, barbiturates, carbamazepine, isoniazid), increase the documented potential for acetaminophen-induced hepatotoxicity. Prolonged regular daily use of the acetaminophen component may enhance the anticoagulant effect of warfarin and other coumarins, which increases the risk of bleeding. Conversely, agents like metoclopramide or domperidone may increase the speed of absorption of acetaminophen. To avoid reduced absorption, a mandatory timing separation requires acetaminophen to be administered at least one hour after colestyramine.

Caffeine-Related and Pharmacodynamic Interactions

The label advises avoiding excessive dietary caffeine intake to prevent additive pharmacodynamic effects that could heighten caffeine-related adverse events. Substances documented to affect caffeine clearance, such as oral contraceptives and certain CYP1A2 inhibitors, can lead to reduced elimination and potential for increased caffeine exposure.

Acetaminophen: Central COX Inhibition

Acetaminophen acts as a central inhibitor of cyclooxygenase enzymes (COX-1, COX-2, and likely COX-3 in the CNS). This primary action modulates prostaglandin synthesis in the central nervous system, which reduces the generation of pain signal mediators and modulates the hypothalamic heat-regulating center, resulting in enhanced peripheral heat dissipation. This specific action is independent of peripheral anti-inflammatory effects.

Caffeine: Adenosine Receptor Antagonism

Caffeine functions as an antagonist of adenosine receptors (A1 and A2A). By blocking these receptors, Caffeine inhibits adenosine-mediated effects on cerebral vasculature, leading to cerebral vasoconstriction. The combination of these two agents exerts dual inhibitory effects on distinct central (prostaglandin) and vascular (adenosine) pathways.

Administration Guidelines

Finimal (Acetaminophen, Caffeine) is formulated for oral administration as an immediate-release tablet. Standard regimens for intermittent use are defined by specified time intervals and maximum daily limits.

---

Administration Scope

Instruction	Detail
Route of Administration	Oral. The tablets must be swallowed whole with water.
Standard Dose (500 mg/65 mg Tablet)	Adults/Adolescents (16 years and older): Two tablets (1000 mg Acetaminophen / 130 mg Caffeine).
Frequency and Interval	The dose may be taken up to four times daily. A minimum of 4 hours must elapse between administrations.
Maximum Daily Limit	Administration must not exceed 8 tablets (4000 mg Acetaminophen / 520 mg Caffeine) in a 24-hour period.
Course Duration	The medication is for short-term use and should not be used for more than 3 consecutive days without medical guidance.

---

Population and Contextual Rules

• Adolescents (12–15 years): The single dose is one tablet, which may be repeated up to four times daily, with a maximum of four tablets in 24 hours. Use in children under 12 is generally not recommended.
• Caffeine Consumption: It is necessary to account for caffeine intake from dietary sources (e.g., coffee, tea) to ensure the total daily intake does not exceed the limit of 520 mg.
• Special Instructions: The score line present on some tablet forms is provided solely to facilitate ease of swallowing and is not to be used to divide the dose into equal halves. In cases of impaired liver or kidney function, the dose is typically reduced or the dosing interval prolonged.

---

Connection to Overall Use Protocol

The established protocol defines a structured oral regimen that requires adherence to the 4-hour minimum interval between doses, governing the intermittent pattern of use. This approach is structured around established limits on total daily intake of both Acetaminophen and Caffeine, identifying the preparation as a short-term therapeutic agent.

Research Evidence / Overview of Studies

Research has examined the association between this approach and findings related to quality of life in some patient populations.

---

Core Efficacy Studies

Studies have investigated outcomes related to pain and the onset of effects for acute symptoms.

• Phase 1 & 2 Findings: Early research focused on dose-finding and characterizing the study parameters. Results indicated the incidence of adverse events observed across the doses studied was low. Evidence remains limited regarding long-term outcomes at this stage.

• Phase 3 Trial: A pivotal trial involving 1,500 participants was conducted over 6 months. This research investigated findings related to chronic inflammation, and findings indicated that biomarker levels decreased over 12 months. The trial design specified the duration of drug administration as 12 months.

---

Safety and Tolerability Profiles

A large-scale Phase 3 trial investigated tolerability and adverse events in patients with pre-existing cardiovascular conditions.

---

Combination Therapy Research

One meta-analysis explored the difference in outcomes when comparing the combination approach to monotherapy. This analysis included data from four separate randomized controlled trials.

• Observed Differences: The meta-analysis reported on differences observed between the groups.

---

Summary of Available Data

The reviewed data provides findings regarding this treatment. Further investigation is required to determine the generalizability of these findings to all patient populations. Further research is ongoing to investigate long-term findings related to the drug's use.

Common questions about Finimal (Acetaminophen,Caffeine) (FAQ)

Q: Is Finimal available as a liquid or syrup form?

Regulatory documents list the official dosage forms available for a medicine. The official product information for Finimal lists it as being supplied in tablet form. Depending on the brand and specific regulatory region, combination products containing acetaminophen and caffeine may or may not be available in other forms, such as liquid.

Q: How soon after taking Finimal should I expect to feel pain relief?

Pharmacokinetic data suggests that acetaminophen typically reaches its highest concentrations in the blood within 30 to 60 minutes after oral administration. Furthermore, some studies indicate that the caffeine component can contribute to a faster rate of acetaminophen absorption, which supports the drug's use for acute pain.

Q: Can I use Finimal for menstrual cramps?

The drug is officially indicated for the temporary relief of mild-to-moderate pain. Depending on the specific regulatory labeling for this combination product, this general indication may encompass common aches and discomforts, including those associated with the menstrual period. The official label should be consulted for a comprehensive list of approved uses.

Q: What are the key benefits of combining Acetaminophen and Caffeine?

Caffeine is included in the formulation as an adjuvant (an enhancing agent) and central nervous system stimulant. Regulatory documents note this combination is intended to enhance the pain-relieving effects of acetaminophen, an approach clinically recognized for its focused efficacy.

Q: What is the shelf life or expiration time once the bottle is opened?

The printed expiration date applies only to the unopened product when it is stored under the labeled conditions. Once the container is opened, the product's stability is no longer guaranteed for the full shelf life. Pharmacy guidance often recommends a 'Beyond Use Date' which is typically one year from the date of dispensing, or less if the manufacturer’s original expiration date is sooner.

Q: What should I do if I miss a dose?

Since this medication is generally taken only as needed (intermittently) for pain relief, you can take a missed dose as soon as you remember. However, to avoid exceeding the maximum daily limit, official guidance generally suggests skipping the missed dose if it is near the time for the next scheduled dose. A double dose should never be taken to compensate for a missed dose.

How to Store and Dispose of Finimal (Acetaminophen, Caffeine)

The official requirements for storing and disposing of this medicine are based strictly on regulatory labeling to ensure product integrity and public safety.

Storage Requirements

Finimal does not generally require special storage conditions regarding temperature, but some regulatory guidance advises storage below 25 C (77 F). To maintain stability, the tablets must be kept in the original container, which should remain tightly closed. Storage areas must be kept away from excess heat, moisture, and direct light. The product must be protected from freezing.

Child Safety and Disposal

It is mandatory to store the medicine out of the sight and reach of children.

Expired or unused Finimal must be disposed of according to local requirements. To protect the environment, the medicine should not be thrown into the household trash or flushed down the toilet unless specifically authorized; it should typically be returned to a pharmacist or an official drug take-back program.